The bully of the ribbon and the value of pink

November is here, let the pink tide finally recede. This year the tide was especially aggressive.

Like Kramer in the clip below, I saw and heard some ribbon bullies this month, no big surprise, although in October when the ribbon bullies get going, it's to encourage men to don pink in public, generally under the banner of 'Are you man enough to wear pink?' The subtext is that pink is only acceptable for men in October, and only when others challenge you to wear it. That they expect compliance is self-defeating; succumbing to peer pressure is hardly an edifying quality, and no mark of maturity will ever be found where there is also such a massive cultural disclaimer as the meaning of pink in October.

Anyway, how much money would you guess was raised for the fight against breast cancer this past month? Between all the competing charity fundraisers, who knows, but here's something that will give you some scale to gauge the potential amount.

SUSAN G AND THE BENJAMIN'S

Technically, National Breast Cancer Awareness Month is not a cause or a campaign, it's an organization founded and sponsored chiefly by big Pharma (AstraZeneca). It has a 20-30 member Board of Sponsors, one of which is the extraordinarily high-profile Susan G. Komen For the Cure. This non-profit raises cash at a staggering clip: Between the Passionately Pink days, the promotional arrangements and the endless stream of 5k runs, they raise about $1 million* a day.

Every day of the year.

That's $357,000,000 in gross revenue annually the past two years ($368 milliion in 2008, $346 million in 2009). Compared to perennial charitable behemoths like the United Way, the Mayo Clinic Foundation, and the American Red Cross (which see around $3 to 6 billion in total revenue annually), it's not even close. But Susan G. Komen is just one (very large) organization chasing breast cancer's tail.

Add them all up, it's in the billions. Throwing money at a disease has never proven effective, so I can only hope they're doing more than that.

By Ross Bonander

* I arrived at this figure rather crudely but not without accuracy. I took the total amount of gross revenue Susan G. Komen for the Cure reported in 2008 and 2009, divided it in half, then divided that figure by 365, then rounded up by about $20,000.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap